BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ$70.6
Market Cap
$13.47B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
491 of 924
Rank in Industry
284 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
BMRN Insider Trading Activity
BMRN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $14,278,693 | 14 | 100 |
Related Transactions
| Burkhart Erin | GVP, Chief Accounting Officer | 0 | $0 | 3 | $361,903 | $-361,903 |
| Mueller Brian | EVP, Chief Financial Officer | 0 | $0 | 1 | $375,950 | $-375,950 |
| Ajer Jeffrey Robert | EVP, Chief Commercial Officer | 0 | $0 | 1 | $414,550 | $-414,550 |
| Guyer Charles Greg | EVP, Chief Technical Officer | 0 | $0 | 2 | $851,679 | $-851,679 |
| Davis George Eric | EVP, Chief Legal Officer | 0 | $0 | 3 | $5.37M | $-5.37M |
| BIENAIME JEAN JACQUES | director | 0 | $0 | 4 | $6.9M | $-6.9M |
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. …
Insider Activity of BioMarin Pharmaceutical Inc.
Over the last 12 months, insiders at BioMarin Pharmaceutical Inc. have bought $0 and sold $14.28M worth of BioMarin Pharmaceutical Inc. stock.
On average, over the past 5 years, insiders at BioMarin Pharmaceutical Inc. have bought $658,092 and sold $24.48M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,625 shares for transaction amount of $314,469 was made by Alles Mark J (director) on 2022‑10‑31.
List of Insider Buy and Sell Transactions, BioMarin Pharmaceutical Inc.
| 2025-03-06 | Sale | Guyer Charles Greg | EVP, Chief Technical Officer | 7,034 0.0037% | $71.28 | $501,355 | -0.86% | |
| 2025-02-24 | Sale | Burkhart Erin | GVP, Chief Accounting Officer | 1,344 0.0007% | $68.38 | $91,903 | +2.91% | |
| 2024-11-12 | Sale | Guyer Charles Greg | EVP, Chief Technical Officer | 5,278 0.0028% | $66.37 | $350,324 | -0.71% | |
| 2024-08-13 | Sale | Burkhart Erin | GVP, Chief Accounting Officer | 714 0.0004% | $90.00 | $64,260 | -25.95% | |
| 2024-05-30 | Sale | Mueller Brian | EVP, Chief Financial Officer | 5,000 0.0027% | $75.19 | $375,950 | -5.78% | |
| 2024-05-28 | Sale | Davis George Eric | EVP, Chief Legal Officer | 40,850 0.0215% | $74.51 | $3.04M | -5.66% | |
| 2024-05-10 | Sale | BIENAIME JEAN JACQUES | director | 20,000 0.0105% | $81.14 | $1.62M | -13.13% | |
| 2024-05-09 | Sale | BIENAIME JEAN JACQUES | director | 20,000 0.0105% | $81.62 | $1.63M | -13.82% | |
| 2024-05-02 | Sale | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | 5,000 0.0026% | $82.91 | $414,550 | -15.86% | |
| 2024-05-02 | Sale | Davis George Eric | EVP, Chief Legal Officer | 1,850 0.001% | $85.01 | $157,269 | -15.86% | |
| 2024-04-12 | Sale | BIENAIME JEAN JACQUES | director | 20,000 0.0104% | $91.26 | $1.83M | -22.99% | |
| 2024-04-11 | Sale | BIENAIME JEAN JACQUES | director | 20,000 0.0105% | $90.99 | $1.82M | -22.28% | |
| 2024-04-10 | Sale | Burkhart Erin | GVP, Chief Accounting Officer | 2,286 0.0012% | $90.00 | $205,740 | -21.14% | |
| 2024-03-28 | Sale | Davis George Eric | EVP, Chief Legal Officer | 24,602 0.0132% | $88.34 | $2.17M | -18.47% | |
| 2024-03-06 | Sale | BIENAIME JEAN JACQUES | director | 1,000 0.0005% | $86.71 | $86,713 | -11.92% | |
| 2024-03-05 | Sale | BIENAIME JEAN JACQUES | director | 1,000 0.0005% | $85.51 | $85,510 | -10.82% | |
| 2024-03-05 | Sale | FUCHS HENRY J | President, Worldwide R&D | 35,341 0.0186% | $85.18 | $3.01M | -10.82% | |
| 2024-03-05 | Sale | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | 4,000 0.0021% | $87.07 | $348,280 | -10.82% | |
| 2024-02-27 | Sale | BIENAIME JEAN JACQUES | director | 1,000 0.0005% | $90.35 | $90,350 | -12.78% | |
| 2024-02-09 | Sale | BIENAIME JEAN JACQUES | director | 15,000 0.0078% | $88.28 | $1.32M | -7.92% |
Total: 964
*Gray background shows transactions not older than one year
Insider Historical Profitability
20%
| BIENAIME JEAN JACQUES | director | 474994 0.249% | $33.53M | 26 | 321 | +29.88% |
| Mueller Brian | EVP, Chief Financial Officer | 72159 0.0378% | $5.09M | 2 | 32 | +36.78% |
| Davis George Eric | EVP, Chief Legal Officer | 56157 0.0294% | $3.96M | 4 | 73 | +5.04% |
| MEIER RICHARD A | 104032 0.0545% | $7.34M | 4 | 9 | +42.46% | |
| PRICE FREDRIC D | Chief Executive Officer | 79285 0.0416% | $5.6M | 1 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$961,890,236 | 276 | 22.46% | $13.1B | |
$211,610,344 | 91 | 38.45% | $7.13B | |
BioMarin Pharmaceutical Inc. (BMRN) | $2,765,836 | 72 | 20.00% | $13.47B |
$108,876,545 | 67 | 72.81% | $7.52B | |
$2,449,191,716 | 58 | 16.50% | $73.17B |
BMRN Institutional Investors: Active Positions
| Increased Positions | 289 | +45.02% | 18M | +9.59% |
| Decreased Positions | 287 | -44.7% | 16M | -8.75% |
| New Positions | 88 | New | 3M | New |
| Sold Out Positions | 98 | Sold Out | 5M | Sold Out |
| Total Postitions | 644 | +0.31% | 184M | +0.84% |
BMRN Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $1.67M | 12.31% | 23.51M | +889,613 | +3.93% | 2024-12-31 |
| Vanguard Group Inc | $1.38M | 10.14% | 19.37M | +93,531 | +0.48% | 2024-12-31 |
| Primecap Management Co/Ca/ | $1.29M | 9.52% | 18.19M | -678,264 | -3.6% | 2024-12-31 |
| Dodge & Cox | $1.05M | 7.72% | 14.75M | +847,917 | +6.1% | 2024-12-31 |
| Capital Research Global Investors | $924,494.00 | 6.8% | 12.99M | +2M | +23.79% | 2024-12-31 |
| Viking Global Investors Lp | $747,931.00 | 5.5% | 10.51M | +757,257 | +7.76% | 2024-12-31 |
| State Street Corp | $648,429.00 | 4.77% | 9.11M | +289,161 | +3.28% | 2024-12-31 |
| Ameriprise Financial Inc | $320,238.00 | 2.36% | 4.5M | +218,766 | +5.11% | 2024-12-31 |
| Norges Bank | $254,029.00 | 1.87% | 3.57M | -49,672 | -1.37% | 2024-12-31 |
| Elliott Investment Management L.P. | $249,084.00 | 1.83% | 3.5M | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.